Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 230 participants.

Also called NCT02689180

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 230 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02689180
Other papers using this trial's data
  • Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial European heart journal, 2019-11-21 DOI, PubMed 31424503

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02689180. Randomized; quadruple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients
Acronym
ReBIC-1
Condition
Heart Failure
Intervention (Drug)
Placebo
Intervention (Drug)
Furosemide
Lead sponsor
Hospital de Clinicas de Porto Alegre (class: other)
Collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico (class: other government)

Record details

Record id
cardio:ct-nct02689180
Content hash
f56f5a1e22e4fea5d111d14fc7323ecf4845e982c492ed10944b92500b560aed